skip to main content
Banner Image

Clinical Trials

Clinical Trials

Title Start Date Principal Name
A Phase 1B/2 Study of Viagenpumatucel L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non Small Cell Lung Cancer (The “Durga” Trial) 10/10/2018 Jeffery Schneider, MD
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma 02/06/2016 Mary O’Keeffe, MD
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer 11/14/2016 Mary O’Keeffe, MD
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (Cypress 2) 12/26/2017 Jeffery Schneider, MD
A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High PD-L1 Expression (CYPRESS 1) 12/26/2017 Jeffery Schneider, MD
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen 02/28/2017 Alexander Hindenburg, MD
A Randomized, Double-blind, Placebo-controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-CABO) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) 03/27/2018 Mary O’Keeffe, MD
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)   Mary O’Keeffe, MD
A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with… 10/18/2018 Eva Chalas, MD
ALLIANCE 011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial 08/01/2017 Nina D’Abreo, MD
Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer: BWEL Breast Cancer Weight Loss Study 08/29/2016 Nina D’Abreo, MD
Evaluation of HbA1c in Oncology Patients Beginning Intravenous Treatment 04/26/2018 Eva Chalas, MD
Examination of Intestinal Microbiome in Multiple Myeloma Patients   Marc Braunstein, MD, PhD
GEODE: Registry of Guardant360® Use and Outcomes in People with Advanced Cancer Including: Module 1: Non-Small Cell Lung Cancer (NSCLC) 06/22/2018 Jeffery Schneider, MD
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) 02/15/2017 Nina D’Abreo, MD
N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total… 01/13/2012 Prashanti Atluri, MD
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Breast Cancer 09/24/2015 Nina D’Abreo, MD
ONT-380-206: Phase II Randomized, Double-Blinded, Controlled Study of Tucatinib vs. placebo in combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma 05/05/2017 Nina D’Abreo, MD
S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer 09/08/2016 Nina D’Abreo, MD
S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvan 02/02/2017 Nina D’Abreo, MD
Top